Purification and Immunological Characterization of Recombinant Antigens Expressed in the Form of Insoluble Aggregates (Inclusion Bodies)

  • Udo Reischl
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 13)


In the field of clinical diagnosis the determination of specific antibodies against distinct structural or functional antigenic proteins of a given pathogen is the most commonly used diagnostic tool for the detection of infections. Although most of the established test systems still use natural antigen from different sources, the advent of nucleic acid engineering opens up the possibility of producing proteins of limited natural availability as well as designing novel proteins using in vitro mutagenesis techniques. Recombinant technology has already proven to be an excellent alternative for the production of specific antigens, that are able to improve sensitivity as well as specifity. In general, the production of recombinant antigens for diagnostic purposes is inexpensive compared to the use of purified natural antigens. The major problems associated with the setup of recombinant test systems are, of course, the identification of those antigens or antigenic determinants that guarantee a safe serological diagnosis (see  Chapter 1 and  Chapter 2) and the expression of these fragments with high efficiency.


Inclusion Body Recombinant Antigen Natural Antigen Sonication Buffer Uninduced Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Takacs B. J and Gierard M.-F. (1991) Preparation of clinical grade proteins produced by recombinant DNA technologies. J Immunol Methods 143, 231–240PubMedCrossRefGoogle Scholar
  2. 2.
    Sambrook J, Fritsch E. F., and Maniatis T (1989) Molecular Cloning A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor, NYGoogle Scholar
  3. 3.
    Reischl U, Gerdes C, Motz M, and Wolf H (1995) Expression and purification of a 23-kDa protein encoded by Epstein-Barr virus and characterization of its immunological properties. J Virol. Meth 57, 71–85.CrossRefGoogle Scholar
  4. 4.
    van Grunsven W. M. J., van Heerde E. C, de Haard H. J W., Spaan W. J. M., and Middeldorp J M. (1993) Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. J. Virol 67, 3908–3916.PubMedGoogle Scholar
  5. 5.
    Gorgievski-Hrisoho M., Hinderer W., Nebel-Schickl H, Vornhagen R., Sonneborn H.-H., Wolf H., and Siegl G. (1990) Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzymelinked immunosorbent assay technology. J. Clin Microbiol. 28, 2305–2311.PubMedGoogle Scholar
  6. 6.
    Motz M, Fan J., Seibl R., Jilg W, and Wolf H (1986) Expression of the Epstein-Barr virus 138-kDa early protein in E coli for the use as antigen diagnostic tests. Gene 42, 303–312.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1998

Authors and Affiliations

  • Udo Reischl
    • 1
  1. 1.Institute for Medical Microbiology and HygieneUniversity of RegensburgGermany

Personalised recommendations